IL17A and airway hyperresponsiveness: Preliminary findings indicated that JPH203 administration suppressed allergen-induced airway hyperresponsiveness, neutrophil accumulation, and IL-17 production in the lungs, whereas dexamethasone treatment failed to demonstrate any significant improvement (manuscript in preparation).